the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
May 15, 2018 –An increasing number of women who are diagnosed with breast cancer are opting for multigene sequencing instead of the more limited testing for only BRCA1/ BRCA2 mutations, according to a new report. The findings come from the ICanCAre study, published …
Breast cancer: Multigene sequencing replaces BRCA tests Read more »
May 05, 2018 – The American Food and Drug Administration (FDA) just approved the combination of Dabrafenib (Tafinlar)/Trametinib (Mekinist) to be administered together for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has …
Dabrafenib/Trametinib-Combo approved for BRAF-positive anaplastic thyroid cancer Read more »
February 17, 2018 – In a new study, published in JAMA Oncology online on February 15, 2018, a comparison of the performance of 6 prognostic signatures for estrogen receptor (ER) –positive breast cancer was performed in a secondary analysis of a randomized …
Breast Cancer: Performance of prognostic signatures Read more »
January 13, 2018 – The American Food and Drug Administration (FDA) has just approved the first treatment for breast cancer with a certain inherited genetic mutation. At first glance, this announcement may be just one in the series of announcements by the …
Olaparib Tablets (Lynparza): For breast cancer with BRCA gene mutation Read more »
December 25, 2017 – The American Food & Drug Administration (FDA) has approved two genetic tests to identify genetic alterations in tumors. The FoundationOne CDx (F1CDx) genomic test and the MSK-IMPACT Tumor Profiling test both can help to guide physicians in …
FDA-cleared genomic profiling tests to guide cancer treatment Read more »
Dezember 21, 2017 – Erdheim–Chester disease ((ECD), also known as Erdheim–Chester syndrome or polyostotic sclerosing histiocytosis) is a form of a bone marrow borne blood cancer. It is a rare disease characterized by the abnormal multiplication of a specific type …
Vemurafenib (Zelboraf) for BRAF V600E positive Erdheim-Chester Disease (ECD) Read more »
November 24, 2017 – New research indicates that one-size treatment for one form of blood cancer likely does not fit all, particularly when it comes to ethnic differences of patients. Thus, African-American men are three times more likely to be …
Cancer is not like cancer: Ethnic background matters Read more »
November 05, 2017 – For some patients knowingly or not knowingly suffering from depression, the upcoming period of the year (i.e., the winter season in the Northern Hemisphere) with grey days and over-porportionally long nights, might be a difficult one. Should …
Theragenomic medicine: Accurate treatment response prediction in depressed patients Read more »
August 18, 2017 – B-cell precursor acute lymphoblastic leukemia (ALL) is a aggressive and rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell. In the United States, …
Besponsa: Is this really a viable new treatment for ALL? Read more »
June 16, 2017 – Patient education in pharmacogenetics, the central component of theragenomic and personalized medicine and individualized drug safety is an important issue. Not only needs the individual patient to understand what pharmacogenetics, or more precisely, pharmacogenetic testing can …
Development of a patient education video about pharmacogenetics Read more »